Abstract
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood.v120.21.2746.2746
Journal: Blood | Publication Date: Nov 16, 2012 |
Citations: 12 |
A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.
Join us for a 30 min session where you can share your feedback and ask us any queries you have